A prerequisite for the prolonged infusion of a drug via a totally implanted drug delivery system is that the drug solution must be sufficiently stable at physiological temperatures to endure the time intervals between drug replacement or pump refills. Consequently, the stability of the chemotherapeutic agents can influence the dosing accuracy and ultimately the achievement of the desired therapeutic goal. The chemical stability of the pharmaceutical preparation Trimetrexate (TMQ) glucuronate, a non-classical, lipophilic antifolate, has been character&d. Incubation of TMQ (prepared in sterile water to a concentration of 5.0 mg/ml) in sterile, amber glass vials at 37°C for 56 days resulted in a degradation rate constant of 0.0134 + 0.002 day-' and a half-life of 51.6 + 0.8 days. The major degradation product has been identified as (2,4-diamino-5-methyl-6-carboxaldehyde)quinazoline.
INTRODUCTION
Trimetrexate, 2,4-diamino-5-methyl-6[(3,4,5-trimethoxyanilino)-methyl]quinazoline (TMQ), was originally synthesized by Elslager and Davoll'. It is a potent inhibitor of dihydrofolate reductase (DHFR) [5,6,7,8- the central nervous system (CNS) and, therefore, greater efficacy than MTX against CNS neoplasms. The importance of antifolate concentration and exposure time in determining toxic and therapeutic effects both in vitro and in vivo in experimental animal tumors has been established6qg. Studies in experimental animal systems have also shown that biological response to antifolates is determined by exposure time and is selective for individual tissues"-".
These findings suggest a therapeutic rationale for the prolonged infusion of TMQ at rigidly controlled dose rates which achieve steady-state TMQ plasma levels toxic to neoplastic cells but below the toxic threshold of bone marrow cells from that individual patient. With the advent of totally implanted drug delivery systems, therapy involving prolonged intravenous or, in the case of regional chemotherapy", intra-arterial infusions can be accomplished on an out-patient basis with minimal patient risk and significant savings in hospital an patient care expenses.
Portable drug delivery systems, both external and implanted, allow constant drug infusion rates at the desired sites for extended durations. However, a prerequisite for prolonged drug infusion via a totally implanted drug delivery system is that the drug solution must be sufficiently stable at physiological temperatures to endure the time intervals between drug replacement or pump refills. Consequently, the stability of the chemotherapeutic agents can influence the dosing accuracy and ultimately the achievement of the desired therapeutic goal. The present study was designed to characterize the stability of the TMQ drug preparation (Trimetrexate glucuronate) in sterile, amberized glass vials during prolonged incubation (8 weeks) at 37°C.
EXPERIMENTAL

Materials
Trimetrexate glucuronate (50 mg TMQ/vial) and 2,4-diamino-5-methyl-6-carboxaldehyde-quinazoline (AMCQ) were obtained from Warner-Lambert/Parke-Davis, Pharmaceutical Research Devision, Ann Arbor, MI, U.S.A. All other chemicals were high-performance liquid chromatography (HPLC) or analytical grade. Amberized glass vials (10 ml capacity with rubber septa and crimp closures) and N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) were obtained from Pierce (Rockford, IL, U.S.A.). Sterile plastic (1.0 ml) syringes (Becton, Dickinson & Co., Rutherford, NJ, U.S.A.) were used for sampling.
Kinetic procedures
Trimetrexate glucuronate injection (50-mg vial) was reconstituted in 10.0 ml sterile water to yield a concentration of 5.0 mg TMQ/ml. The reconstituted solution was aseptically transferred to sealed, sterile, amber glass vials. Triplicate sample solutions were prepared. A 0.2-ml aliquot of the samples was removed from each amber vial and signified the samples at zero time. The vials were then incubated in a constant-temperature water bath at 37°C and 0.2-ml aliquots were removed from each vial at the following times: 3, 10, 14, 17, 21, 25, 28, 31, 39, 42, 47, 49 and 56 days. All samples were frozen immediately upon acquisition at -30°C in tightly capped plastic tubes until TMQ analysis.
HPLC assay of TMQ
TMQ standards, quality control and experimental (incubate) samples were diluted 1:5 with methanol-water (5050, v/v) and 2.0 ~1 of the diluted samples were injected onto an HPLC reversed-phase column (Hewlett-Packard MOS Cs, 10 cm x 2 mm I.D., 5 ,um) using the Hewlett-Packard Model 1090 high-performance liquid chromatograph and autosampler. The chromatographic conditions were: mobilephase, methanol-acetonitrile-O.05 M (NH4)H2P04 buffer (12: 18:70, v/v/v); flowrate, 0.5 ml/min; detector, Hewlett-Packard Model 1040 diode array UVVIS detector monitoring at 254 nm wavelength and scanning between 200 and 400 nm. The chromatographic peak area integration was acquired using the Hewlett-Packard 3392A integrator/printer. Calibration curves were constructed by plotting the integrated peak area of TMQ as a function of the drug concentration. The TMQ concentrations of unknown samples were calculated using the results of a least squares linear regression analysis of the calibration data.
Gas chromatography-mass spectrometry
The Hewlett-Packard Model 5987A gas chromatography-mass spectrometry (GC-MS) apparatus equipped with both electron impact (EI) and methane chemical ionization (CI) modes of operation was used in the identification of the major product of TMQ degradation. Separation of the trimethylsilyl (TMS) derivatives of TMQ and its degradation products was accomplished using a fused-silica capillary column (5 m x 0.32 mm I.D.) coated with a cross-linked methyl silicone liquid phase (0.17 mm film thickness). Chromatographic conditions were: injection port and GC-MS interface oven temperatures were 300°C; GC column oven temperature was programmed to hold at the initial temperature of 80°C for 0.1 min, and then increase at a rate of 20"C/min up to the final temperature of 300°C; for EI operation, the ion source temperature was 25O"C, electron energy was 70 eV, and the scan range was from 70 to 600 a.m.u.; for methane CI operation, the ion source temperature was 200°C electron energy was 230 eV, and the scan range was from 130 to 600 a.m.u.
Trimethylsilylation of TMQ and its degradation products was accomplished using MSTFA. Aliquots of 0.1 ml of both the zero-time and 56-day incubation samples were vacuum dried and the residue derivatized in 0.25 ml MSTFA for 2 h at 85°C. A 0.5~~1 volume of the reaction mixture was injected for GC-MS analysis.
RESULTS AND DISCUSSION
TMQ assay validation
Under the described chromatographic conditions, the retention time of TMQ was 2.03 min. The integrated peak areas were directly proportional to the drug concentrations over the range of TMQ concentrations tested (0.50-5.00 mg/ml).
Triplicate sets of the calibration standards were assayed on each of three consecutive days. Linear regression of the data from each day was obtained. The reproducibility of the daily standard curves had coefficients of variation which ranged between 1.7 and 4.8%.
The accuracy and precision of the method were assessed by seeding quality control samples at drug concentrations of 1.00 and 4.00 mg TMQ/ml. Triplicate 201 401 wavelength (nm) Fig. 1 . Results of peak purity evaluation of TMQ peak in HPLC assay procedure. Peak purity is confirmed by three perfectly superimposed UV-VIS absorption spectra.
quality control samples were assayed on each of three consecutive days. The precision of the assay was found to have coefficients of variation ranging between 1.9 and 4.4%. The concentration means for the seeded control samples were found to be within -1.3-+ 3.2% of the theoretical values.
TMQ assay specljicity
The purity of the TMQ peak in the HPLC assay described here was confirmed with a peak purity evaluation program available on the HP 1090 HPLC system equipped with the HP 1040 diode array detector. This program automatically collects UV-VIS absorption spectral data at the upslope, apex and downslope of an eluting peak. In the peak purity analysis, the upslope spectrum of a peak is recorded and becomes a reference spectrum. The apex spectrum of the peak then becomes the reference and the upslope spectrum is discarded. The downslope spectrum of the peak is then plotted against the reference (apex) spectrum. Finally, the end-of-peak spectrum is plotted against the reference (apex) spectrum. Peak purity is established by three perfectly superimposed spectra.
When applied to the TMQ incubation samples, three superimposed spectra t=zero time t=Zl days t=56 doys RETENTION TIME (MINUTES) Fig. 2 . HPLC chromatograms (24 injections) of zero-time, 21-day and 56-day incubation samples showing TMQ (peak B) disappearance and degradation product (peak A) accumulation with increasing incubation time.
( Fig. 1 ) of the drug peak (peak B in Fig. 2 ) resulted, thus verifying that the TMQ peak was uncontaminated by any potentially coeluting products.
Degradation kinetics
The integrated peak areas of the incubated samples were compared to those resulting from injections of standard solutions. The concentration versus time (in days) data were then entered on semi-log plots as shown in Fig. 3 . The stability profile of TMQ can be described by the simple monoexponential decay as given in eqn. 1:
where Co is the initial concentration at time zero, k is the rate constant for degradation of TMQ in day-', t is the time in days, and C, is the concentration of TMQ at incubation time (t). The parameters of the least squares regression line for eqn. 1 are summarized in Table I . The mean ( f S.D.) rate constant for drug degradation was 0.0134 f 0.0002 day-' and, therefore, the mean half-life (0.693/k) for TMQ at 37°C in glass was 51.6 f 0.8 days. If one defines the maximum allowable percent drug loss before either drug replacement or pump refill as lo%, then the maximum allowable incubation (or infusion) time between TMQ refill or replacement based on the rate constant of degradation obtained in this study would be 7.9 days.
Products of TMQ degradation
Since the half-life of TMQ in this preparation at 37°C is only 51.6 days, the degradation product(s) would be expected to accumulate in significant amounts even in the relatively short incubation period of 1-2 weeks. Fig. 2 shows a chromatogram (HPLC) of TMQ samples (2.0 ~1 injections) from zero-time, 21-&y and 56-day incubations. It is evident from Fig. 2 that as the parent drug peak (B) progressively decreases with increasing incubation time, other earlier eluting peaks (primarily peak A) are increasing. It is to be noted that most of the early eluting peaks (including peak A) are absent or only marginally present in the zero-time or TMQ standard solutions. Using the diode array UV-VIS detector, UV spectral data were gathered for both TMQ and its major degradation product, peaks B and A in Fig. 2 , respectively. These spectral data are shown in Fig. 4 . The major degradation product has a distinctly different UV spectrum, with an absorbance maximum at 253.nm and a secondary peak at 332 nm. TMQ's UV spectrum elicits two primary peaks at 215 and 243 nm and a small secondary peak at 330 nm.
The GC-MS analysis of the vacuum-dried residues from the zero-time and 56-day incubation samples derivatized with MSTFA revealed a large peak (tR = 5.0 min) in the 56-day sample which was absent in the zero-time sample. Both samples had a large peak eluting at 9.2 min, corresponding to authentic TMQ-bisTMS. When analysed in the EI mode, the mass spectrum of TMQ-bisTMS ( Fig . 4 . UV-VIS absorption spectra of TMQ (peak B in Fig. 2 ), degradation product (peak A in Fig. 2 ), and authentic AMCQ. linkage. The degradation product's mass spectrum (Fig. 6a) GC-MS analysis of these samples in the methane Cl mode resulted in base peaks of TMQ and its degradation product at the corresponding [M + I]+ ions (m/z 514 and 347, respectively). Also characteristic of methane CI, each mass spectrum included an [M + 29]+ ion, due to the addition of (C2Hs). Finally, the fragmentation patterns were consistent with TMS derivatives showing a significant [M -15]+ peak. The TMQ-bisTMS CI mass spectrum retained as its second largest peak the ion at m/z 331.
Additional evidence for the presence of an aldehyde in the incubated samples was obtained with the 2,4_dinitrophenylhydrazine test for aldehydes and ketones14.
The zero-time sample tested negative for aldehydes and ketones (no precipitate formation). However, the 56-day sample elicited a strong positive response with the immediate formation of an orange-red precipitate (the insoluble dinitrophenylhydrazone).
The mass spectral and chemical data suggested the identity of the degradation product as AMCQ. Mass spectral (Fig. 6 ) and UV-VIS absorption spectral (Fig. 4) analysis of authentic AMCQ confirmed this conclusion.
In conclusion, the chemical stability of the pharmaceutical preparation (Trimetrexate glucuronate) of this non classical antifolate has been evaluated. Incubation in sterile, amber glass vials at 37°C for 56 days resulted in a degradation rate constant of 0.0134 _+ 0.0002 day-' and a half-life of 51.6 f 0.8 days. The major degradation product has been identified as AMCQ. Ten percent TMQ degradation would occur by 7.9 days of incubation under these conditions. Therefore, use of this drug preparation in implanted drug delivery systems would necessitate weekly pump refill or replacement if one sets 10% degradation as the maximum allowed.
